Saturday, 20 July 2019

Strides Vivimed JV receives approval for Albendazole Tablets

12 December 2018 | News

This is the second generic approval by US FDA for Albendazole Tablets.

Image credit- washingtonpost.com

Image credit- washingtonpost.com

Strides  Pharma Science  Limited  (Strides)  has announced that its 50:50 JV Strides Vivimed Pte. Ltd, Singapore has received approval for Albendazole Tablets USP 200 mg from the United States Food & Drug Administration (US FDA).

This is the second generic approval by US FDA for Albendazole Tablets.

Albendazole Tablets is a generic version of Albenza Tablets of Amneal Pharmaceuticals, Inc.

According  to  IQVIA  MAT  data,  the  US  market  for  Albendazole  Tablets  USP  200  mg  is approximately US$ 100 Million.  

Albendazole  is  an  anthelmintic  medication  used  to  treat  certain  infections  caused  by tapeworm.  Albendazole  prevents  newly  hatched  insect  larvae  (worms)  from  growing  or multiplying in the body. 

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls